Dr. Eva Agaiby, PharmD

Dr. Eva Agaiby is the President and Director of Clinical Trials & Regulatory Affairs at Clinical Investigation Specialists, Inc. Dr. Agaiby is a pharmacist with over twenty years of experience in multiple therapeutic areas. She is recognized as an expert panelist in both academic and regulatory platforms.

As a licensed healthcare professional and clinical research investigator, Dr. Agaiby works directly with the FDA advisory committee to offer expert opinions on various clinical trials. As the President and chief executive, Dr. Agaiby oversees a robust network of clinical research sites and their respective staff. She oversees all medical study teams at CIS Research, offering innovative solutions to operational challenges. Dr. Agaiby also represents CIS Research annually at a variety of industry conferences.

Education

• Doctor of Pharmacy (PharmD), Midwestern University (1997-1999)
• Bachelor of Science (BS), Pharmacy, Midwestern University (1994-1997)
• Bachelor of Health Science, Health Science- Illinois Benedictine University

Awards, Recognitions & Community Service

• Key Executive Professional, Presidential Who's Who Publication (May 2010)
• Honorary Research Award, Midwestern University (Jan 1995)

Publications

• Agaiby, Eva. Comment Submission, Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments, Food and Drug Administration. Posted 6 December, 2019.

• Jeffrey Gudin, Richard Rauck, Charles Argoff, Eva Agaiby, Joseph Gimbel, Nathaniel Katz, Stephen K Doberstein, Mary Tagliaferri, Margit Tagliaferri, Jeffrey Potts, James Wild, Lin Lu, Suresh Siddhanti, Martin Hale, John Markman, Long-term Safety and Tolerability of NKTR-181 in Patients with Moderate to Severe Chronic Low Back Pain or Chronic Noncancer Pain: A Phase 3 Multicenter, Open-Label, 52-Week Study (SUMMIT-08 LTS), Pain Medicine, Volume 21, Issue 7, July 2020, Pages 1347–1356, https://doi.org/10.1093/pm/pnz169
• Markman, Johna,*; Gudin, Jeffreyb; Rauck, Richardc; Argoff, Charlesd; Rowbotham, Michaele; Agaiby, Eva; Gimbel, Josephg; Katz, Nathanielh; Doberstein, Stephen K.i; Tagliaferri, Maryi; Lu, Lini; Siddhanti, Sureshi; Hale, Martinj. SUMMIT-07: a randomized trial of NKTR-181, a new molecular entity, full mu-opioid receptor agonist for chronic low-back pain. PAIN 160(6):p 1374-1382, June 2019. | DOI: 10.1097/j.pain.0000000000001517 PAIN